Αποτελέσματα Αναζήτησης
27 Νοε 2018 · Treatment of acute VTE and superficial vein thrombosis. Recommendations 1 and 2. For pregnant women with acute VTE, the American Society of Hematology (ASH) guideline panel recommends antithrombotic therapy compared with no antithrombotic therapy (strong recommendation, high certainty in evidence about effects ⊕⊕⊕⊕).
1 Ιαν 2007 · Recently, Gris and colleagues reported that treatment with 40 mg enoxaparin daily in pregnant women with a thrombophilia (factor V Leiden, prothrombin gene mutation, or protein S deficiency) and one previous pregnancy loss after 10 weeks gestation, resulted in a significantly higher live birth rate (86%) compared with low-dose aspirin alone (29 ...
The factor V Leiden (FVL) mutation is the most common known genetic factor that predisposes to thrombosis. 3,4 Retrospective studies have reported an increased risk of venous thromboembolism (10–25%) among pregnant women heterozygous for the FVL mutation. 5-9 However, limited prospective data exist to define the risk of venous thromboembolism ...
26 Οκτ 2017 · For women with heterozygous factor V Leiden mutation, the absolute risk of pregnancy associated VTE was 1.1% overall (95% credible interval 0.3% to 1.9%), 0.4% antepartum (0.1% to 0.9%), and 2.0% postpartum (0.9% to 3.7%).
The purpose of this document is to review common thrombophilias and their association with maternal venous thromboembolism risk and adverse pregnancy outcomes, indications for screening to detect these conditions, and management options in pregnancy.
24 Ιουν 2020 · Although numerous replication case-control studies have attempted to determine the association between Factor V Leiden (FVL) 1691G > A mutation and susceptibility to Recurrent pregnancy loss (RPL), there have been confliction among the results of various ethnic groups.
4 Δεκ 2010 · In one of the few randomized trials in this area, Gris and colleagues 52 reported that treatment of women with a thrombophilia (factor V Leiden, prothrombin gene mutation, or protein S deficiency) and one previous pregnancy loss after 10 weeks gestation with 40-mg enoxaparin daily resulted in a significantly higher live birth rate (86% ...
